Moleculin Biotech (NASDAQ:MBRX) Getting Somewhat Positive News Coverage, Study Finds

News coverage about Moleculin Biotech (NASDAQ:MBRX) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Moleculin Biotech earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.6264264354969 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment’s analysis:

Shares of Moleculin Biotech (NASDAQ MBRX) opened at $1.80 on Monday. Moleculin Biotech has a 12 month low of $0.71 and a 12 month high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.14) earnings per share for the quarter.

Separately, ValuEngine upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

TRADEMARK VIOLATION WARNING: “Moleculin Biotech (NASDAQ:MBRX) Getting Somewhat Positive News Coverage, Study Finds” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-moleculin-biotech-mbrx-share-price.html.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply